ReviewHLA2017
In celebration of Ruggero Ceppellini: HLA in transplantation.
Review in HLA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 28 citations in OpenAlex.
- Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson's disease.Frontiers in immunology · 2024Article
- Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.JAMA network open · 2023Article
- HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Identification of peripheral CD154Clinical and experimental immunology · 2021Article
- Article
- Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.Bone marrow transplantation · 2018Review
- The role of MHC genes in contagious cancer: the story of Tasmanian devils.Immunogenetics · 2017Review
- Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles.PLoS genetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The availability of hematopoietic cell transplantation as curative therapy for blood disorders has been dramatically improved through a better understanding of the human leukocyte antigen (HLA) barrier. Although a fully compatible unrelated donor is preferable, transplantation from donors with a limited degree of HLA mismatching is associated with acceptable outcomes in many cases. Research on the limits of HLA mismatching, and the features that define permissible HLA mismatches will continue to enable transplantation to be more broadly available to patients in need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.